title: Blockade of behavioral effects of bretazenil by flumazenil and ZK 93,426 in pigeons.
abstract: Benzodiazepine receptor partial agonists manifest full efficacy in preclinical tests of anxiolytic drug action but do not fully reproduce the discriminative stimulus effects of benzodiazepine receptor full agonists in pigeons. The partial agonist, bretazenil, binds to both diazepam-sensitive and diazepam-insensitive GABAA receptors. Previous studies have suggested a role for each of these receptor populations in some behavioral effects of bretazenil in pigeons. A possible role for these receptor subtypes in the behavioral effects of bretazenil was further investigated through drug interaction studies with the benzodiazepine receptor antagonists, flumazenil and ZK 93,426. Whereas flumazenil binds with high affinity to both receptor isoforms, ZK 93,426 binds preferentially to diazepam-sensitive binding sites. Bretazenil markedly increased punished responding of pigeons without significantly affecting nonpunished responding. In pigeons discriminating the full benzodiazepine receptor agonist, midazolam, from saline, bretazenil produced only 60-75% maximal effect. Flumazenil and ZK 93,426 neither increased punished responding nor substituted for midazolam, but dose-dependently blocked the effects of bretazenil on punished responding. Flumazenil also dose-dependently blocked the effects of bretazenil in midazolam-discriminating pigeons, whereas ZK 93,426 only attenuated this effect. These results indicate that bretazenil's actions as a partial agonist at diazepam-sensitive benzodiazepine receptors mediate increases in punished responding and substitution for the discriminative stimulus effects of midazolam in pigeons. The differences in the effects of flumazenil and ZK 93,426 on the discriminative stimulus effects of bretazenil suggest a potential contribution of diazepam-insensitive sites to this behavioral effect.
authors.affiliation: Addiction Research Center, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, USA.
authors.forename: J M
authors.initials: JM
authors.lastname: Witkin
authors.forename: J B
authors.initials: JB
authors.lastname: Acri
authors.forename: S
authors.initials: S
authors.lastname: Gleeson
authors.forename: J E
authors.initials: JE
authors.lastname: Barrett
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D001570:Benzodiazepinones / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D002243:Carbolines / Q000494:pharmacology*; D010856:Columbidae; D003216:Conditioning, Operant / Q000187:drug effects; D004192:Discrimination, Psychological / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005442:Flumazenil / Q000494:pharmacology*; D018756:GABA Antagonists / Q000494:pharmacology*; D018757:GABA Modulators / Q000494:pharmacology*; D008297:Male; D008874:Midazolam / Q000494:pharmacology; D011678:Punishment; D018079:Receptors, GABA / Q000187:drug effects / Q000378:metabolism
chemical_list: D001570:Benzodiazepinones; D002243:Carbolines; D018756:GABA Antagonists; D018757:GABA Modulators; D018079:Receptors, GABA; D005442:Flumazenil; C042568:ZK 93426; C054626:bretazenil; D008874:Midazolam